69 related articles for article (PubMed ID: 32084238)
1. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
Kessler T; Baumeier A; Brand C; Grau M; Angenendt L; Harrach S; Stalmann U; Schmidt LH; Gosheger G; Hardes J; Andreou D; Dreischalück J; Lenz G; Wardelmann E; Mesters RM; Schwöppe C; Berdel WE; Hartmann W; Schliemann C
Transl Oncol; 2018 Dec; 11(6):1271-1282. PubMed ID: 30125801
[TBL] [Abstract][Full Text] [Related]
2. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Pasqualini R; Koivunen E; Kain R; Lahdenranta J; Sakamoto M; Stryhn A; Ashmun RA; Shapiro LH; Arap W; Ruoslahti E
Cancer Res; 2000 Feb; 60(3):722-7. PubMed ID: 10676659
[TBL] [Abstract][Full Text] [Related]
3. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth.
Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G
Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor: a neglected role in cancer biology.
Li H; Yu Y; Gao L; Zheng P; Liu X; Chen H
J Thromb Thrombolysis; 2022 Jul; 54(1):97-108. PubMed ID: 35763169
[TBL] [Abstract][Full Text] [Related]
5. The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations.
Faqihi F; Stoodley MA; McRobb LS
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356840
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes.
Nassar E; Hassan N; El-Ghonaimy EA; Hassan H; Abdullah MS; Rottke TV; Kiesel L; Greve B; Ibrahim SA; Götte M
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066023
[TBL] [Abstract][Full Text] [Related]
7. Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Berdel WE; Harrach S; Brand C; Brömmel K; Berdel AF; Hintelmann H; Schliemann C; Schwöppe C
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256235
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
[TBL] [Abstract][Full Text] [Related]
9. [Advance in studies on NGR peptide modified liposome and its anti-tumor performance].
Wang Y; Chen J; Lin AH; Fang Y
Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(13):2041-5. PubMed ID: 24079222
[TBL] [Abstract][Full Text] [Related]
10. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
12. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
[TBL] [Abstract][Full Text] [Related]
13. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
14. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
